[Influence of adjuvant therapy on survival of patients with pancreatic carcinoma of body and tail: a report of 137 cases].
To investigate the effect of adjuvant therapy on the treatment of carcinoma of the body and tail of pancreas. The clinical data of 137 patients with carcinoma of the body and tail of pancreas, 91 males and 46 females, aged 58.9 (24 - 76), of which 38 underwent radical resection, 24 underwent palliative resection, and 75 did not undergo resection, and 58 of which underwent adjuvant therapy, were analyzed. The overall 3-year survival rate was 10.7% for the whole group, 27.3% for the radical resection group, 4.2% for the palliative resection, and 4.5% for the no resection group. The median survival time (MST) was 8 months for the whole group, 15 months for the radical resection group, 8 months for the palliative resection group, and 6 months for the no resection group. The 3-year survival rate was 13.9% for the patients undergoing adjuvant therapy and 7.2% for those without adjuvant therapy, and the MST was 11 months for those undergoing adjuvant therapy, and 5 months for those without adjuvant therapy. Intra-arterial therapy and radiation therapy were protective factors for those whose cancerous tissues were not radically resected (OR = 1.56, 95% CI: 1.04 - 2.35, P = 0.033). Adjuvant therapy significantly improves the survival of the patients with pancreatic carcinoma of the body and tail. The clinical effect of intra-arterial therapy is better than those of radiation therapy and chemotherapy.